UK drug update - December 2004

Published: 1-Dec-2004
Regulatory


Servier Laboratories has launched Protelos. The 2g sachets contain the bone disease treatment strontium ranelate.

Pfizer has marketed Inspra containing 25mg or 50mg tablets of the aldosterone antagonist eplerenone.

Novartis has brought out 40mg tablets of the angiotensin II antagonist valsartan under the trade name of Diovan.

Ivax has made available Qvar Easi-Breathe containing 50µg or 100µg per dose of the corticosteroid beclometasone dipropionate.

AstraZeneca has introduced Zomig Rapimelt. The tablets contain 5mg of the 5-hydroxytryptamine-1 agonist zolmitriptan.

GSK has marketed Avandamet. The tablets contain the thiazolidinedione rosiglitazone and the biguanide metformin in the combinations 2mg/1000mg and 4mg/1000mg.

Serono Pharmaceuticals has launched Raptiva powder and solvent for solution for injection. The reconstituted product yields 100mg/mL of the selective immunosuppressive agent efalizumab.

Sandoz has added lisinopril/

hydrochlorothiazide tablets to its product range. The tablets contain the ACE inhibitor lisinopril and the thiazide diuretic hydrochlorothiazide in the combinations 10mg/12.5mg and 20mg/12.5mg. The company has also brought out Rhumalgan modified-release tablets containing 75mg (Rhumalgan SR) or 100mg (Rhumalgan XL) of the nonsteroidal anti-inflammatory drug diclofenac.

Merck, Sharp & Dohme has marketed Singulair Paediatric Granules containing 4mg of the leukotriene receptor antagonist montelukast.

Almus Pharmaceuticals has added the following to its range: 5mg tablets of the potassium-sparing diuretic amiloride; 200mg and 300mg tablets of the antimalarial quinine sulphate; and 50mg capsules of the opiate analogue tramadol hydrochloride.

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Subscribe now